Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 28.45
+0.10 (0.35%)
Sep 8, 2026, 1:41 PM CST
Prince Pharmaceutical Revenue
Prince Pharmaceutical had revenue of 616.64M TWD in the half year ending June 30, 2026, with 81.46% growth. This brings the company's revenue in the last twelve months to 1.22B, up 53.43% year-over-year. In the year 2025, Prince Pharmaceutical had annual revenue of 1.06B with 53.07% growth.
Revenue (ttm)
1.22B
Revenue Growth
+53.43%
P/S Ratio
0.86
Revenue / Employee
5.67M
Employees
216
Market Cap
1.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.06B | 366.18M | 53.07% |
| Dec 31, 2024 | 690.03M | -63.30M | -8.40% |
| Dec 31, 2023 | 753.33M | 40.80M | 5.73% |
| Dec 31, 2022 | 712.53M | 271.45M | 61.54% |
| Dec 31, 2021 | 441.08M | 145.28M | 49.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.40B |
| Excelsior Biopharma | 936.92M |
| Anxo Pharmaceutical | 878.88M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Winston Medical Supply | 632.80M |
| Johnson Chemical Pharmaceutical Works | 577.93M |
| General Biologicals | 260.23M |